Piper Sandler restated their overweight rating on shares of Mesoblast (NASDAQ:MESO – Free Report) in a research note issued to investors on Friday,Benzinga reports. They currently have a $24.00 price target on the stock, up from their previous price target of $15.00.
Other research analysts have also issued reports about the stock. Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a research note on Thursday, January 30th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.
Check Out Our Latest Stock Report on Mesoblast
Mesoblast Price Performance
Hedge Funds Weigh In On Mesoblast
Several institutional investors and hedge funds have recently bought and sold shares of MESO. R Squared Ltd acquired a new position in Mesoblast in the fourth quarter valued at approximately $30,000. Lindbrook Capital LLC raised its position in Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after purchasing an additional 901 shares during the period. Signaturefd LLC lifted its stake in shares of Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after purchasing an additional 1,213 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Mesoblast during the 4th quarter worth about $134,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
- Five stocks we like better than Mesoblast
- How to Invest in the FAANG Stocks
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- Retail Stocks Investing, Explained
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- MarketBeat Week in Review – 02/03 – 02/07
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.